Trial Profile
Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Cervical cancer; Vulvovaginal cancer
- Focus Adverse reactions
- 22 Aug 2023 Status changed from active, no longer recruiting to completed.
- 19 Jun 2023 Planned End Date changed from 31 Oct 2021 to 30 Jan 2024.
- 19 Jun 2023 Planned primary completion date changed from 31 Oct 2021 to 30 Jan 2024.